Boston Scientific to Release Latest Clinical Trial Results on Market-Leading TAXUS(R) Coronary Stent Systems at EuroPCR

Boston Scientific to Release Latest Clinical Trial Results on Market-Leading TAXUS(R) Coronary Stent Systems at EuroPCR

May 10, 2006

Results to Include Nine-Month Data on TAXUS(R) Liberte(TM) Stent

    NATICK, Mass., May 10 /Xinhua-PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) announced the schedule
of the Company's major events and press announcements at
the Paris Course on Revascularization (EuroPCR), which runs
from May 16 to 19 in Paris, France.

    "The data we will present at EuroPCR builds on the
continued strength and leadership of the TAXUS brand of
coronary stent systems," said Paul LaViolette, Chief
Operating Officer of Boston Scientific. "We expect
this data will offer further evidence of the performance
and durability of our current drug-eluting stent platform,
as well as the deliverability and efficacy of our second
generation product, the TAXUS Liberte paclitaxel-eluting
coronary stent system."

    Tuesday, May 16 (all times are Paris time)

    - Symposium on drug-eluting stents. At 1:30 p.m., the
Company will host a symposium entitled "The Great
Debate on drug-eluting stents," chaired by Jean Marco,
M.D., in Room 1 of the Palais des Congres, 2 Place de la
Porte Maillot, Paris. The symposium will focus on key
issues related to drug-eluting stent (DES) usage in daily
practice and will review the options and decision criteria
for the usage of the TAXUS(R) paclitaxel-eluting coronary
stent systems versus other platforms through evidence-based
medicine.

    - Peripheral Interventions trial data. At 1:43 p.m.,
nine-month results from the RENAISSANCE clinical trial will
be presented by Krishna Rocha-Singh, M.D., F.A.C.C., the
study's principal investigator, at a late-breaking trials
session in Room 2. RENAISSANCE is a prospective,
multi-center trial designed to confirm the safety and
efficacy of the Express(R) SD stent for renal artery
stenting. At 1:45 p.m., one-year results from the MELODIE
clinical trial will be presented by Luc Stockx, M.D., at a
late-breaking trials session in Room 2. MELODIE is a
prospective, multi-center trial designed to confirm the
safety and efficacy of the Express(TM) Vascular LD stent
for the treatment of iliac artery lesions. The Company will
issue a press release on the MELODIE results at this time.

    - ATLAS nine-month data. At 5:20 p.m., nine-month
results from the ATLAS clinical trial will be presented by
Mark Turco M.D., F.A.C.C., the study's co principal
investigator, at a late-breaking trials session in Room 1.
The ATLAS clinical trial is a global, multi-center, pivotal
study designed to support U.S. Food and Drug Administration
approval of TAXUS Liberte(TM), the Company's second
generation, paclitaxel-eluting stent system. ATLAS studies
the TAXUS Liberte stent system, compared to a case-matched
control group of TAXUS Express(TM) and TAXUS Express2(TM)
patients from TAXUS IV and TAXUS V de novo studies. ATLAS
is the first global trial of a second-generation DES. The
Company will also issue a press release at this time.

    - TAXUS VI long-term data. At 5:52 p.m., the Company
will release three-year results from its TAXUS VI clinical
trial, which evaluates the safety and efficacy of a
moderate-release formulation of its TAXUS Express
paclitaxel-eluting stent in high-risk patients, including
long lesions, small vessels and diabetics. (The Company's
current commercialized product uses a slow-release
formulation.) The results will be presented by Keith
Dawkins, M.D., the study's co-principal investigator, at a
late-breaking trials session in Room 1. The Company will
also issue a press release at this time.

    - S.T.E.N.T Registry nine-month update. At 6:02 p.m.,
nine-month results from the Strategic Transcatheter
Evaluation of New Therapies (STENT) registry will be
presented by Thomas Stuckey, M.D., at a late-breaking
trials session in Room 1. This large, independent,
prospective, multi-center registry evaluates the
comparative late clinical outcomes of paclitaxel- and
sirolimus-eluting coronary stents among
"real-world" cases and clinical situations,
including diabetics and other high-risk patients. With a
planned enrollment of more than 8,000 patients, the STENT
registry is the largest study of its kind in the United
States.

    Boston Scientific will present its latest innovations
at booth #F14, including the iLab Ultrasound Imaging System
-- a completely functional IVUS system designed to be
installed into a cath lab.

    Boston Scientific is a worldwide developer,
manufacturer and marketer of medical devices whose products
are used in a broad range of interventional medical
specialties. For more information, please visit:
http://www.bostonscientific.com .

    This press release contains forward-looking statements.
The Company wishes to caution the reader of this press
release that actual results may differ from those discussed
in the forward-looking statements and may be adversely
affected by, among other things, risks associated with
clinical trials, the regulatory approval process,
reimbursement policies, commercialization of new
technologies, litigation, the Company's overall business
strategy and other factors described in the Company's
filings with the Securities and Exchange Commission.
    
    For more information, please contact:

     Geraldine Varoqui
     Boston Scientific PR Manager International
     Tel:   [phone]
     Email: [e-mail]
   
     Maren Koban
     BSC press office
     Tel:   [phone]
     Email: [e-mail]

SOURCE  Boston Scientific Corporation